Cargando…
Response of Patients with Taxane-Refractory Advanced Urothelial Cancer to Enfortumab Vedotin, a Microtubule-Disrupting Agent
Enfortumab vedotin (EV), a nectin-4-directed antibody conjugated to monomethyl auristatin E (MMAE), has been approved for patients with advanced urothelial carcinoma (aUC) previously treated with platinum-based chemotherapy and immune inhibitors. Taxane agents and MMAE share antitumor mechanisms thr...
Autores principales: | Miyake, Makito, Nishimura, Nobutaka, Miyamoto, Tatsuki, Shimizu, Takuto, Ohnishi, Kenta, Hori, Shunta, Morizawa, Yosuke, Gotoh, Daisuke, Nakai, Yasushi, Torimoto, Kazumasa, Fujii, Tomomi, Fujimoto, Kiyohide |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867573/ https://www.ncbi.nlm.nih.gov/pubmed/36691441 http://dx.doi.org/10.1155/2023/1024239 |
Ejemplares similares
-
Probiotics enhances anti‐tumor immune response induced by gemcitabine plus cisplatin chemotherapy for urothelial cancer
por: Miyake, Makito, et al.
Publicado: (2022) -
Effect of bladder distension on arginine vasopressin secretion in rats
por: Morizawa, Yosuke, et al.
Publicado: (2019) -
Efficacy and safety of dutasteride with tadalafil add-on therapy in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia
por: Gotoh, Daisuke, et al.
Publicado: (2022) -
Utility of a penile compression device for the quality of life in male patients with urinary incontinence after prostatectomy (the MORE study): a randomized prospective study
por: Gotoh, Daisuke, et al.
Publicado: (2023) -
Trends in the Treatment Outcomes and Features of Cryptorchidism in Boys: A Single-Institute Experience
por: Hori, Shunta, et al.
Publicado: (2020)